Health Economics addresses the efficient allocation of scarce resources in healthcare. It examines how health services are financed, delivered, and evaluated, and how decisions affect costs, outcomes, and distributional equity. In the life sciences environment, Health Economics is closely linked to reimbursement decisions, pricing strategies, and Health Technology Assessment (HTA).
Objectives and Typical Questions
Health economic analyses aim to make the economic consequences of therapies, diagnostics, or care concepts transparent. Typical questions include: What costs arise in the care pathway? What clinical outcomes are achieved? How do additional costs relate to additional benefit compared to standard of care? Depending on the perspective, indirect costs (e.g., productivity losses) are also considered in addition to direct medical costs.
For sponsor teams, it is important to recognize that Health Economics is not merely “cost accounting”: it concerns the justification of an innovation’s value. This value is discussed in many systems in relation to clinical efficacy, safety, quality of life, and real-world care. This results in requirements for endpoints, data collection, and narrative preparation for dossiers. In early development, Health Economics is therefore frequently used to refine Target Product Profiles and support evidence-based go/no-go decisions.
Methods: Cost-Effectiveness and Cost-Benefit Assessment
Common methodological approaches include cost-effectiveness analyses (e.g., cost per life year gained) and cost-utility analyses, often using QALYs as the benefit measure. Cost-benefit analyses, by contrast, attempt to express benefit in monetary terms, which can be methodologically and ethically controversial. The choice of method depends on the research question, available data, and requirements of assessment bodies.
A practical component is modeling: Markov models or discrete event simulations are used to represent long-term courses when clinical trials have only limited observation periods. Transparency is essential: assumptions, parameter sources, and sensitivity analyses must be documented in a comprehensible manner. Deterministic and probabilistic sensitivity analyses are often combined to test the robustness of conclusions against uncertainty.
HTA in Germany and Europe
In Germany, health economic assessment in the context of reimbursement is closely linked to the AMNOG procedure and early benefit assessment. The focus is initially on additional benefit compared to an appropriate comparator therapy; economic arguments play a role in subsequent price negotiations. In other European countries (e.g., UK, Scandinavia, Benelux), formal cost-effectiveness analyses are more institutionalized.
At the EU level, cooperation in the area of HTA is also evolving to harmonize methodology and evidence requirements. For manufacturers, this means: Health Economics strategies must be planned early and aligned with clinical development, endpoint selection, and real-world evidence strategies. In multi-country programs, a clear “evidence generation roadmap” is helpful, incorporating both clinical trials and registry and routine data.
Data Sources: Studies, Registries, and Real-World Evidence
Health economic models use data from randomized trials (efficacy, adverse events), from care data (routine data, claims, registries), and from patient-reported outcomes (quality of life). For transferability to routine practice, it is important that assumptions regarding adherence, resource utilization, and care pathways are realistic. Real-world evidence can fill critical gaps here, but brings challenges related to bias, data quality, and confounding.
In implementation, clear data management and analysis plans are necessary. CROs frequently support study design, selection of quality-of-life measurement instruments, and preparation of input data for economic models. Consistency of terminology and coding is also important so that clinical and economic datasets can be cleanly integrated. Additionally, it should be determined early whether country-specific cost catalogs, DRG systems, or drug price lists must be used as input.
Practical Pitfalls and Implementation in Projects
Common misunderstandings arise when health economic endpoints are integrated into clinical planning too late. Then suitable measurement instruments, time points, or comparative data are missing. Equally critical are unclear perspectives (payer, societal, hospital) and missing sensitivity analyses. For communication with HTA bodies, a consistent narrative style that integrates clinical and economic evidence is also important.
Another pitfall is transferability between countries. Care reality, prices, treatment pathways, and reimbursement logic differ; therefore, country-specific adaptations are often needed. A sound evidence synthesis concept and transparent model documentation reduce queries and accelerate assessments. On the project side, it should be determined early which data interfaces, validation checks, and review cycles are necessary to avoid “last minute” changes before submission.
In addition to HTA, the perspective of hospitals and healthcare providers is also gaining importance, particularly for new diagnostics, digital applications, or inpatient care pathways. Then, in addition to drug costs, process costs, personnel effort, and potential savings in other budgets must be made visible. For evidence generation, this may mean that additional resource utilization data or patient-centered outcomes are collected in studies. Clear planning of “value communication” is also advisable so that clinical, patient-related, and economic arguments are consistent across scientific advice, dossiers, and reimbursement discussions.
FAQ
What does QALY stand for and why is it relevant?
QALY stands for “quality-adjusted life year” and combines life expectancy and quality of life into a single metric. It is frequently used to make benefit comparable between therapies and to derive cost-effectiveness ratios.
Is Health Economics only relevant for reimbursement?
No. Health economic analyses also support internal decisions, e.g., prioritization of development programs, selection of endpoints, or planning of real-world evidence studies.
Which data are particularly critical for economic models?
Essential are valid efficacy and safety data, reliable information on resource utilization, appropriate quality-of-life measures, and transparent assumptions including sensitivity analyses.
Regulatory References (Selection)
- AMNOG / SGB V (Germany: early benefit assessment and pricing)
- EU HTA Regulation (EU) 2021/2282 (framework for joint HTA work)
- ICH E6(R3) Good Clinical Practice (data quality and patient protection as the basis for robust evidence)